Clinical trials: SARS CoV 2 Virus
COVID-19
Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above
This is a randomized, blinded, positive-controlled study to evaluate the immunogenicity and safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, in population aged 18 years old and above（negative antibody against…
- Trial name
- NCT05663086
- Testing
- One dose group, Two doses group, Aged 18-59 years
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
COVID-19
Impact of New Variants and Vaccines on the Course of COVID-19
Novel coronavirus disease (COVID-19), caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, was first reported in December 2019 in Wuhan, China.
- Trial name
- COVID-19 (NCT05384886)
- Testing
- Polymerase chain reaction
- Where
- Turkey (Türkiye)
- Volunteers
- 15,967 people
- Sponsor
- Izmir Katip Celebi University
Post COVID-19 Condition, Unspecified, SARS-CoV2 Infection
PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway
The goal of this clinical trial is to compare treatment with oral Paxlovid (nirmatrelvir/ritonavir) and placebo for acute COVID-19 as an intervention to prevent long-COVID (post-COVID-19 condition) in adults aged 18-64 years old.
- Conditions
- Post COVID-19 Condition, Unspecified, SARS-CoV2 Infection, COVID-19
- Trial name
- PanoramicNOR (NCT05852873)
- Testing
- Nirmatrelvir/ritonavir
- Where
- Norway
- Volunteers
- 2,000 people
- Sponsor
- Haukeland University Hospital
Coronavirus Infection
Observational Study in Diagnosed Patients COVID-19, Supported on an Outpatient Basis. (COVID-PSL)
COVID-19 is an infection linked to a new coronavirus: SARS-CoV-2, which appeared in Wuhan in China at the end of 2019, and which has since spread around the world, responsible for a new major pandemic, which is upsetting the…
- Trial name
- COVID-PSL (NCT04402905)
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
COVID-19
Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases
The purpose of the study is to evaluate the safety and immunogenicity of the investigational CpG 1018/Alum-adjuvanted recombinant SARS-CoV-2 trimeric spike (S)-protein subunit vaccine (SCB-2019) in adult participants with stable…
- Trial name
- COVID-19 (NCT05012787)
- Testing
- CpG 1018/Alum-adjuvanted SCB-2019 vaccine, Havrix
- Where
- 4 sites in Ukraine
- Volunteers
- 1 people
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Patient Safety
Non-COVID Patient-safety Incidents Reported by General Practitioners in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study.cRisis
The COVID-19 epidemic is causing a global health crisis. In France, it has imposed a major reorganization of the healthcare system. This emergency reorganization is unprecedented. It involved first, second and third line care.
- Trial name
- PSI-RECORd-GP (NCT04346121)
- Testing
- GPs reports of potential patient safety incidents, non-COVID-19 related
- Where
- France
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital
SARS-COV2, COVID19
Identifying Functional and Psycho-social Complaints After Hospitalization for SARS-CoV-2 Infection( COVID 19)- REPERCOV
Since December 2019, China and then the rest of the world have been affected by the rapid spread of a new coronavirus infection called SARS-CoV-2 (severe acute respiratory syndrome coronavirus), the clinical expression of which…
- Trial name
- REPERCOV (NCT04561154)
- Testing
- questionnaire
- Where
- France
- Volunteers
- 134 people
- Sponsor
- Centre Hospitalier le Mans
SARS-CoV-2 Infection, Hematologic Malignancy
Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors
The goal of this observational study is to compare the immune function and infection mechanism of patients with hematologic tumors and those people without underlying diseases after infection with SARS-CoV-2.
- Trial name
- NCT05683353
- Testing
- None intervention
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
SARS-CoV 2
Severe Acute Respiratory Syndrome-Coronavirus-2 and Loss of Autonomy in the Elderly
In most diseases, older people have less typical symptomatology than that described for younger people. The investigators therefore hypothesize that within the framework of coronavirus disease 19, the clinical pictures in the…
- Trial name
- CovAged (NCT04414319)
- Where
- 5 sites in France, Guadeloupe and 1 more
- Volunteers
- 170 people
- Sponsor
- University Hospital Center of Martinique
Covid19
The Role of CT Chest Scan in the Pre-anesthetic Assessment of Suspected or Confirmed COVID -19 Patients
The role of CT scan of the chest in Pre-anesthetic assessment of the severity of COVID-19 and the correlations between CT measurements of the aortic and pulmonary arteries diameters and severity of pneumonia.
- Trial name
- NCT04560530
- Testing
- Non-enhanced CT scan of the chest
- Where
- Saudi Arabia
- Volunteers
- 76 people
- Sponsor
- Tanta University
Coronavirus, Convalescence
Convalescent Plasma to Stem Coronavirus (CSSC-001)
Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day 28.
- Trial name
- CSSC-001 (NCT04323800)
- Testing
- Anti- SARS-CoV-2 Plasma, SARS-CoV-2 non-immune Plasma
- Where
- 25 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
COVID-19 Pandemic, COVID-19 Vaccines
INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old
This is an open label, phase III trial - immunobridging study. There will be only 1 group in the study. All subjects (12 to 17 years old) will receive INAVAC 5 µg dose.
- Trial name
- NCT06282692
- Testing
- INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated) 5 µg
- Where
- Indonesia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Dr. Soetomo General Hospital
Severe Acute Respiratory Syndrome Coronavirus 2
A Clinical Trial of COVAC-2 in Adults
VIDO has developed a vaccine called COVAC-2. The COVAC-2 study vaccine contains a portion of the SARS-CoV-2 spike protein, called S1.
- Trial name
- NCT05209009
- Testing
- COVAC-2
- Where
- 2 sites in Uganda
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Saskatchewan
COVID, COVID-19
Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19
Facing the challenge of finding an efficient treatment for COVID-19, the viral pneumonia caused by the Coronavirus SARS-Cov-2, this study intended to test if Chloroquine or Hydroxychloroquine, two drugs with strong in-vitro…
- Conditions
- COVID, COVID-19, SARS-CoV 2, Coronavirus
- Trial name
- NCT04420247
- Testing
- Chloroquine, Hydroxychloroquine, standard care
- Where
- Brazil
- Volunteers
- 142 people
- Sponsor
- Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva
SARS-CoV-2, Covid19
COVID-19 Child Health Investigation of Latent Disease in Hamburg
The study measures infection rates and the presence of antibodies for SARS-CoV-2 (COVID-19) among in- and outpatients of all pediatric hospitals, as well as volunteers aged 0 to 18 years in Hamburg, Germany.
- Trial name
- C19CHILD (NCT04534608)
- Where
- Germany
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Chronic Fatigue Syndrome, COVID-19, Long Haul
Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation
This is a single-center, prospective, randomized, double-blind (pharmacotherapy), placebo-controlled, and comprehensive rehabilitation phase II clinical trial to determine the usefulness of pregabalin in a new indication…
- Trial name
- POSTCOVID (NCT05967052)
- Testing
- Pregabalin, Independent walking training, Gradual movement therapy in the ward
- Where
- Poland
- Volunteers
- 23 people
- Sponsor
- National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
Down Syndrome, SARS-CoV-2 Vaccination
Prospective Monitoring of Antibody Response Following COVID-19 Vaccination in Patients With Down Syndrome.
The risk of severe course of SARS-CoV-2 infection in people with Down Syndrome is substantially increased. The risk of death is 3-10 fold higher than in healthy people.
- Trial name
- PRIDE (NCT05145348)
- Testing
- Immune response to Sars-CoV-2 vaccinations; including COVID-19 vaccin Moderna, Comirnaty (Pfizer) and Vaxzevria (AstraZeneca)
- Where
- Netherlands
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht
COVID-19 Vaccination
Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)
This study is to identify any problems and questions with respect to the safety of Comirnaty Injection (Bretovameran) during the post-marketing period.
- Trial name
- NCT06613984
- Testing
- Bretovameran
- Where
- South Korea
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Infections, Antibiotic
Study Evaluating the Impact of Using Triplex Rapid Diagnostic Tests (SARS-CoV-2/Influenza/RSV) on Antibiotic Prescribing
Respiratory infections are very common, especially during winter, and are often caused by viruses such as influenza, SARS-CoV-2 or respiratory syncytial virus (RSV).
- Trial name
- TROD-VILLE (NCT07243249)
- Testing
- TROD
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19, Pulmonary Tuberculosis
Study on Three Doses of an Inactivated COVID-19 Vaccine in Chinese Pulmonary Tuberculosis Patients
This is a randomized, double-blind, parallel-controlled study, for evaluation of safety and immunogenicity of three doses of an inactivated COVID-19 vaccine (CoronaVac) in pulmonary tuberculosis patients aged 18-75 years.
- Trial name
- NCT05148949
- Testing
- Standard dosage inactivated vaccine, Double dosage inactivated vaccine
- Where
- 6 sites in China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention